Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis.

IF 2.5 4区 医学 Q3 ONCOLOGY Oncology Letters Pub Date : 2024-08-28 eCollection Date: 2024-11-01 DOI:10.3892/ol.2024.14648
Huijuan Qian, Si Li, Ziyun Hu
{"title":"Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis.","authors":"Huijuan Qian, Si Li, Ziyun Hu","doi":"10.3892/ol.2024.14648","DOIUrl":null,"url":null,"abstract":"<p><p>Renal insufficiency and/or chronic kidney disease are common comorbidities in patients with lung cancer, potentially affecting their prognosis. The aim of the present study was to assess the existing evidence on the association between renal insufficiency (RI)/chronic kidney disease (CKD) and the overall survival (OS) and disease-free survival (DFS) of patients with lung cancer (LC). Comprehensive electronic searches in the PubMed, Embase and Scopus databases were performed for observational cohort and case-control studies and randomized controlled trials that investigated the association between RI/CKD and the OS and/or DFS of patients with LC. Random-effect models were used, and the combined effect sizes were reported as either standardized mean differences or relative risks, along with 95% confidence intervals (CI). A total of 10 studies were included. The duration of follow-up in the included studies ranged from 12 months to 5 years. Compared with patients with normal renal function, patients with LC with RI/CKD had worse OS rates [hazard ratio (HR), 1.38; 95% CI, 1.16-1.63] but similar DFS rates (HR, 1.12; 95% CI, 0.75-1.67) at follow-up. Subgroup analysis demonstrated a significant association between poor OS and RI/CKD in patients with stage I/II LC [HR, 1.76; 95% CI, 1.30-2.37] but not in patients with stage III/IV LC [HR, 1.18; 95% CI, 0.91, 1.54]. Furthermore, irrespective of the treatment modality i.e., surgery [HR, 1.78; 95% CI, 1.40-2.27] or medical management [HR, 1.37; 95% CI, 1.25-1.50], RI/CKD was notably associated with a poor OS at follow-up. The findings of the present study underscore the adverse impact of RI/CKD on the long-term survival of patients with LC.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11378011/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Letters","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/ol.2024.14648","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Renal insufficiency and/or chronic kidney disease are common comorbidities in patients with lung cancer, potentially affecting their prognosis. The aim of the present study was to assess the existing evidence on the association between renal insufficiency (RI)/chronic kidney disease (CKD) and the overall survival (OS) and disease-free survival (DFS) of patients with lung cancer (LC). Comprehensive electronic searches in the PubMed, Embase and Scopus databases were performed for observational cohort and case-control studies and randomized controlled trials that investigated the association between RI/CKD and the OS and/or DFS of patients with LC. Random-effect models were used, and the combined effect sizes were reported as either standardized mean differences or relative risks, along with 95% confidence intervals (CI). A total of 10 studies were included. The duration of follow-up in the included studies ranged from 12 months to 5 years. Compared with patients with normal renal function, patients with LC with RI/CKD had worse OS rates [hazard ratio (HR), 1.38; 95% CI, 1.16-1.63] but similar DFS rates (HR, 1.12; 95% CI, 0.75-1.67) at follow-up. Subgroup analysis demonstrated a significant association between poor OS and RI/CKD in patients with stage I/II LC [HR, 1.76; 95% CI, 1.30-2.37] but not in patients with stage III/IV LC [HR, 1.18; 95% CI, 0.91, 1.54]. Furthermore, irrespective of the treatment modality i.e., surgery [HR, 1.78; 95% CI, 1.40-2.27] or medical management [HR, 1.37; 95% CI, 1.25-1.50], RI/CKD was notably associated with a poor OS at follow-up. The findings of the present study underscore the adverse impact of RI/CKD on the long-term survival of patients with LC.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾功能障碍与肺癌预后之间的关系:系统回顾和荟萃分析。
肾功能不全和/或慢性肾病是肺癌患者常见的合并症,可能会影响患者的预后。本研究旨在评估肾功能不全(RI)/慢性肾病(CKD)与肺癌患者总生存期(OS)和无病生存期(DFS)之间关系的现有证据。在PubMed、Embase和Scopus数据库中进行了全面的电子检索,以查找研究RI/CKD与肺癌患者OS和/或DFS之间关系的观察性队列研究、病例对照研究和随机对照试验。研究采用随机效应模型,综合效应大小以标准化均值差异或相对风险以及 95% 置信区间 (CI) 的形式报告。共纳入了 10 项研究。纳入研究的随访时间从 12 个月到 5 年不等。与肾功能正常的患者相比,患有RI/CKD的LC患者随访时的OS率较低[危险比(HR),1.38;95% CI,1.16-1.63],但DFS率相似(HR,1.12;95% CI,0.75-1.67)。亚组分析显示,I/II期LC患者的不良OS与RI/CKD之间存在显著关联[HR,1.76;95% CI,1.30-2.37],但III/IV期LC患者的不良OS与RI/CKD之间不存在显著关联[HR,1.18;95% CI,0.91-1.54]。此外,无论治疗方式是手术[HR,1.78;95% CI,1.40-2.27]还是药物治疗[HR,1.37;95% CI,1.25-1.50],RI/CKD 都与随访时的不良 OS 显著相关。本研究结果强调了RI/CKD对LC患者长期生存的不利影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology Letters
Oncology Letters ONCOLOGY-
CiteScore
5.70
自引率
0.00%
发文量
412
审稿时长
2.0 months
期刊介绍: Oncology Letters is a monthly, peer-reviewed journal, available in print and online, that focuses on all aspects of clinical oncology, as well as in vitro and in vivo experimental model systems relevant to the mechanisms of disease. The principal aim of Oncology Letters is to provide the prompt publication of original studies of high quality that pertain to clinical oncology, chemotherapy, oncogenes, carcinogenesis, metastasis, epidemiology and viral oncology in the form of original research, reviews and case reports.
期刊最新文献
Analysis of metastasis‑related risk factors and clinical relevance in adult soft‑tissue sarcoma. Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis. First‑line endocrine therapy for hormone receptor positive and HER‑2 negative metastatic breast cancer: A Bayesian network meta‑analysis. Mesonephric adenocarcinoma of the uterine cervix with a prominent spindle cell component. Neoadjuvant chemotherapy for primary invasive ductal carcinoma of the nipple: A case report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1